Title:
ANTI-CD33 ANTIBODIES AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/006118
Kind Code:
A1
Abstract:
Provided herein are antibodies and antigen-binding fragment thereof targeting CD33, and chimeric antigen receptors (e.g., monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-CD33 antigen-binding fragments thereof. Further provided are engineered immune effector cells (e.g., T cells) expressing the chimeric antigen receptors and methods of use thereof.
Inventors:
ZHANG YAFENG (CN)
ZHU YANLIANG (CN)
TANG WANBING (CN)
YANG SHUAI (CN)
WU SHU (CN)
ZHU YANLIANG (CN)
TANG WANBING (CN)
YANG SHUAI (CN)
WU SHU (CN)
Application Number:
PCT/CN2022/109529
Publication Date:
February 02, 2023
Filing Date:
August 01, 2022
Export Citation:
Assignee:
NANJING LEGEND BIOTECH CO LTD (CN)
International Classes:
C07K16/28; A61K39/395
Domestic Patent References:
| WO2020216238A1 | 2020-10-29 |
Foreign References:
| CN112673022A | 2021-04-16 | |||
| CN112566941A | 2021-03-26 | |||
| CN112189022A | 2021-01-05 |
Other References:
LIU，F. ET AL.: "First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial", BLOOD, vol. 132, no. Supplement 1, 29 November 2018 (2018-11-29), XP086595277, DOI: 10.1182/blood-2018-99-110579
ANONYMOUS: "CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies", CLINICALTRIALS.GOV; NCT03795779, 19 May 2021 (2021-05-19), XP093029253, Retrieved from the Internet [retrieved on 20230306]
GODWIN，C.D.ET AL.: "Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy", LEUKEMIA, vol. 35, no. 9, 15 February 2021 (2021-02-15), XP037553501, DOI: 10.1038/s41375-021-01160-1
DAVER，N.ET AL: "T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments", LEUKEMIA, vol. 35, 5 May 2021 (2021-05-05), XP037500455, DOI: 10.1038/s41375-021-01253-x
CHEN ZE-HUI, LI YUE-YANG, TIAN CHEN: "Research advances in immunotherapy for acute myeloid leukemia", ZHONGGUO SHIYAN XUEYEXUE ZAZHI - JOURNAL OF EXPERIMENTALHEMATOLOGY, ZHONGGUO SHIYAN, XUEYEXUE ZAZHISHE, BEIJING, CN, vol. 28, no. 6, 31 December 2020 (2020-12-31), CN , pages 2089 - 2092, XP009542929, ISSN: 1009-2137, DOI: 10.19746/j.cnki.issn.1009-2137.2020.06.048.
ANONYMOUS: "CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies", CLINICALTRIALS.GOV; NCT03795779, 19 May 2021 (2021-05-19), XP093029253, Retrieved from the Internet
GODWIN，C.D.ET AL.: "Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy", LEUKEMIA, vol. 35, no. 9, 15 February 2021 (2021-02-15), XP037553501, DOI: 10.1038/s41375-021-01160-1
DAVER，N.ET AL: "T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments", LEUKEMIA, vol. 35, 5 May 2021 (2021-05-05), XP037500455, DOI: 10.1038/s41375-021-01253-x
CHEN ZE-HUI, LI YUE-YANG, TIAN CHEN: "Research advances in immunotherapy for acute myeloid leukemia", ZHONGGUO SHIYAN XUEYEXUE ZAZHI - JOURNAL OF EXPERIMENTALHEMATOLOGY, ZHONGGUO SHIYAN, XUEYEXUE ZAZHISHE, BEIJING, CN, vol. 28, no. 6, 31 December 2020 (2020-12-31), CN , pages 2089 - 2092, XP009542929, ISSN: 1009-2137, DOI: 10.19746/j.cnki.issn.1009-2137.2020.06.048.
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF:
Previous Patent: ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
Next Patent: GUIDING METHOD FOR EXTRACORPOREAL CIRCULATION DEVICE AND MONITORING DEVICE
Next Patent: GUIDING METHOD FOR EXTRACORPOREAL CIRCULATION DEVICE AND MONITORING DEVICE